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Abstract 
Parenteral Nutrition-Associated Liver Disease 
(PNALD) causes progressive cholangitis which can 
lead to liver failure and cirrhosis especially in 
infants. Developments in the understanding of its 
pathogenesis are revisited in the context of the need 
for guidelines for its safe management and support  
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Introduction: PNALD: the perfect storm 
Parenteral Nutrition associated liver disease 
(PNALD) is characterised by progressive 
cholestasis associated with a serum conjugated 
bilirubin above34 umol/l during two consecutive 
measurements in patients dependent on parenteral 
nutrition (PN). Fifteen to 40% of adults on long 
term home PN may also develop PNALD, often in 
association with intestinal failure. However 
PNALD has been studied much more intensively in 
the paediatric age group.   
PNALD is commonest and most severe in 
premature neonates, often in association with the 
short bowel syndrome (SBS). The incidence of SBS 
in neonates has been estimated at 24.5 per 100,000 
live births.  Two thirds of these patients will 
develop PNALD with a case fatality rate of 37.5%1 
.  Histologic evidence of cholestasis is seen within 2 
weeks and varying degrees of liver fibrosis within 6 
weeks of starting PN.2 PNALD occurs in up to 70% 
of such patients during 8-14 weeks of PN 3 and may 
progress to cirrhosis and fatal liver failure.  PNALD 
is the leading indication for liver/ intestine 
transplantation in infants.4 Failure to wean infants 
onto enteral feeding increases the need for liver and 
intestinal transplantation.  Immature liver enzyme 
systems, gut mucosal atrophy with loss of hormonal 
output from the unfed gut, intestinal bacterial 
translocation, PN component toxicity, and PN-
mediated exaggerated inflammatory response 
creates a “perfect storm” for progression to liver 
failure. This article revisits the multiple proposed 
aetiologies and pathogenetic mechanisms which 
inform proposed therapeutic strategies in PNALD 
and revisits the evidence-base on how they may 
impact on the progress of this disease.  
The cause of PNALD? : A Crime by omission? 
In the search for the aetiology of PNALD, 
failure or inability to feed the gut is slowly 
replacing PN-related toxicities on centre-stage as 
the prime crime, with bile acids (BA) emerging as 
the main culprit. Healthy subjects economise on 
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intestinal BA by their ileal reabsorbtion and their 
subsequent enterohepatic circulation. Bile acids 
complete the round trip from ileum to liver and 
back about twice during every meal. Luminal BA, 
particularly chenodeoxycholic acid (CDCA)  act as 
ligands to, and activate, the nuclear farnesoid X 
receptor (FXR) in the intestinal epithelium which 
then releases fibroblast growth factor 19 (FGF 19).5  
FGF 19 reaches the liver via the portal vein, and 
after binding to fibroblast growth factor 4 receptor 
(FGFR4) it represses the activity of cholesterol 7 
alpha hydroxylase, a  rate-limiting enzyme in 
hepatic BA synthesis (Figure 1). Disruption of the 
enterohepatic BA circulation by isolation of 
significant lengths of small intestine from exposure 
to food and bile leads to unrepressed hepatic BA 
synthesis which can be corrected by enteral 
administration of chenodeoxycholic (CDCA) but 
not Ursodeoxycholic acid (UDCA).6   Resumption 
of enteral feeding may also help to restore 
enterohepatic BA recirculation. 
Figure 1:  Bile acids (BA) bind to farnesoid 
X receptor( FXR) receptor in terminal ileum 
causing release of fibroblast growth factor 19 ( 
FGF19) which  travels through the portal 
circulation to the liver where it binds to its receptor 
FGFR4 leading to suppression of cholesterol 7 
alpha hydroxylase (CYP7A1), a rate limiting 
enzyme in bile acid synthesis. 
Food and bile acids exert both trophic and 
incretin effects on the intestinal epithelium through 
the bile salt-activated G protein-coupled receptor 
TGR5  which regulates secretion of glucagon-like 
peptides (GLP) 1 and 2 by intestinal endocrine 
cells.7  GLP2 reverses intestinal mucosal atrophy 
while GLP1 restores the insulin response to food 8 
and  its deficiency may be partly responsible for 
glucose intolerance, dyslipidaemia and fatty liver 
seen in some patients on long term PN.     
Gut rest, systemic antibiotics, and mucosal 
atrophy with low IGA are all potential causes of 
intestinal dysbiosis. Overgrowth of gram-negative 
species reminiscent of the dysbiosis observed in the 
gut of cirrhotic patients9 is often present in intestinal 
failure patients.  Small intestinal bacterial 
overgrowth increases gut permeability, allowing 
translocation of bacteria to the liver where 
endotoxin disrupts bile acid transport.10 Here FXR 
and TGR5 have again been implicated.7 FXR 
modulates intestinal epithelial carbonic anhydrase 11 
which regulates luminal pH and therefore bacterial 
levels while TGR5 reduces the expression of 
cytokines like TNF which mediate liver injury.12 
Preventing  irreversible liver damage:  A fishy 
business?  
Infant PN regimens typically infuse 2- 3g/ kg 
/day of soyabean oil as an intravenous fat emulsion 
(soya-IVFE) e.g. Intralipid (Fresenius kabi®) 
containing a high ratio (7:1) of omega-6 to omega-3 
polyunsaturated fatty acids (PUFA), both of which 
compete for the cycloxegenase and lipoxygenase 
pathways (see figure 2). Omega 6 PUFAs, 
predominantly Linoleic acid, are metabolized to 2-
series prostaglandins e.g. PGE 2-series, and 4-series 
leucotrienes e.g. LTB4 via the cyclooxygenase and 
the lipooxygenase pathways respectively. Both 
LTB4 and PGE2 are proinflammatory and 
predominate on the antinflammatory effects of 
PGE1 produced upstream in the same pathway.  In 
contrast omega-3 PUFAs, mainly alpha-linolenic 
acid, docosahexanoic acid (DHA) and 
eicosapentaenoic acid (EPA) are precursors of anti-
inflammatory mediators such as PGE3 and LTB5 
which reduce inflammation. Arachidonic acid 
exerts some of its proinflammatory effect by 
activating the nuclear factor kappa B (NF-κB).13 In 
contrast omega-3 fatty acids inhibit NF-κB 
activation via a peroxisome proliferator-activated 
receptor (PPAR alpha) -dependent pathway. 
Metabolites of omega-3 PUFA that resolve 
inflammation such as resolvin have been shown to 
be hepatoprotective in mice.14 
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Figure 2: Omega-6 fatty acids are predominantly 
metabolized to proinflammtory mediators PGE2 
and LFTB4 while omeg-3 fatty acids are 
predominantly metabolized to anti inflammatory 
mediators PGE3 and LTB5 
The above contrast between different PUFAs  
has led to trials of intravenous  fish oil-based 
emulsions (fish-IVFEs) such as Omegaven 
(Fresenius Kabi®) which has a very low ratio of 
omega-6 to omega-3 PUFA (1:8) mainly containing  
EPA and DPA  ( see figure 2) which modulate 
PPAR alpha.7  Fish oils induce more beta-oxidation 
of fats and reduce lipogenesis thus reducing fat 
deposition in the liver. Compared to plant oils they 
do not contain phytosterols and they have a higher 
content of tocopherol (see below). They still await 
FDA approval and are only used in the USA on a 
compassionate basis.  At lower doses of IVFA fish-
IVFE monotherapy may not meet the infant’s 
requirement for essential fatty acids.  This has 
prompted the manufacture of mixed lipid emulsions 
such as SMOFlipid (Fresenius Kabi®) (30% 
soyabean oil, 30% MCT, 25% olive oil, 15% fish 
oil). 
Soya and other plant- based emulsions also 
contain phytosterols which are potentially 
hepatotoxic. PN abolishes the protective limitation 
on the absorbtion of these plant sterols normally 
afforded by the enteral route.15 El kasmi et al, in a 
model of PNALD in parenterally fed mice with 
intestinal injury, showed that parenteral fish oils 
prevented liver damage and hepatic macrophage 
activation by soya-IVFEs, and that stigmaserol 
promotes cholestasis and Kuppfer cell activation by 
suppressing canalicular bile transport expression 
through antagonism of FXR nuclear receptors.  
Soya IVFEs are also relatively deficient in 
alpha-tocopherol which is a crucial antioxidant in 
the PNALD scenario. The dyslipidaemia and 
hepatic steatosis which characterise both PNALD 
and non-alcoholic fatty liver are associated with the 
accumulation of long chain fatty acids (LCFA) in 
hepatocytes. Disposal of LCFA by hepatic 
mitochondrial B-oxidation is overwhelmed and 
rescue pathways such as peroxisomal beta-oxidation 
and microsomal omega-oxidation are activated. 16   
All this extra oxidative stress produces excess 
reactive oxygen species (ROS) such as superoxide 
which risks overwhelming the enzymes such as 
catalase, superoxide dismutase and the antioxidants 
such as tocopherol and glutathione which scavenge 
free radicals, which would otherwise damage 
hepatocytes through lipid peroxidation of their 
membranes . The burden on tocopherol is further 
exaggerated by oxidative stress secondary to bile 
duct damage. During PNALD vitamin E comes to 
the rescue, not only by means of its classical 
antioxidant function, but also specifically by 
activating xenobiotic receptors such as the pregnane 
X receptor (PXR)17 that wake up auxiliary 
scavenging by conjugation, sulphation and by 
cytochrome P450.  
Coping with PNALD: too many verdicts 
awaited?   
Treatment of PNALD aims to halt the hepatic 
fibroinflammatory reaction before it becomes 
irreversible. Early and repeated attempts to 
introduce enteral feeding are of utmost importance 
as many of the above aetiologies will be reversed. 
Enteral feeding should be carefully advanced and 
PN reduced. 18Even non-advanced minimal enteral 
feeding will help to reverse gut atrophy and restore 
gut hormonal responses (see Table 1). Non-nutritive 
sucking will help to prepare the infant for later 
feeding. Measures that maximize the length and 
function of residual viable bowel should be put in 
place including serial transverse enteroplasty 
(STEP) procedures if appropriate. When enteral 
feeding is contraindicated e.g. early phase of 
necrotizing enterocolitis the following alternative 
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strategies have been studied in the literature: 
IVFE restriction: Restriction of soya IVFE to 
1g/kg/day from the start of PN has been associated 
with significant reduction in PNALD but data on 
detailed nutritional parameters and essential fatty 
acid status have not been studied.  
Cyclic PN: The use of cyclic PN throughout 
the intravenous feeding period has not been 
adequately studied in the literature18 and may be 
poorly tolerated in acutely ill neonates  
Fish IVFE:  Following the first use of fish-
IVFE in a teenager with soy-allergy in 200519 fish-
IVFE administration has been reported in infants 
with PNALD to reverse cholestasis, reduce PN 
duration, reduce mortality, reduce transplant rates 
and to stabilize but not to prevent the early onset of 
liver fibrosis.18   Most of these studies used 
historical PNALD cohorts treated with soy-IVFE. 
A metanalysis in 2012 by Seida et al20 of five 
randomised controlled (RCT) trials and 3 
prospective cohort studies reported insufficiency of 
high quality data to support the use of fish-IVFEs in 
children. The study was heterogeneous and fish-
IVFEs were not always the sole source of lipid in 
the study group. A more recent metanalysis21 of two 
RCTs (Jadad score of 5) and five non-randomized 
studies of fish-IVFE as the sole or partial source of 
intravenous lipids concluded that IVFEs are 
effective in reversing but not in preventing PNAC 
in neonates requiring prolonged nutritional support.  
Mixed IVFEs: The low content of essential 
fatty acids (EFAs) in fish-IVFEs has caused at least 
a theoretical concern that infants with fat 
malabsorbtion receiving low volumes of PN may 
develop EFA deficiency. This has prompted the 
combined use of soy and fish-based IVFEs 
(mixedIVFEs) such a s SMOF (Fresenius Kabi®: 
soya, olive and fish oils, medium chain 
triglycerides) which have been reported to be of 
benefit in PNALD but not adequately compared to 
fish-IVFEs.16 Research in this area is limited by the 
fact that fish oil- based IVFEs are still awaiting 
approval by the FDA in the USA. The ASPEN 2014 
guidelines failed to recommend the use of 
fish/mixed IVFEs pending further trials.22 
Prevention of sepsis: Judicious use of 
antibiotics and other measures that prevent 
peritoneal, catheter-related and other sources of 
sepsis are expected to improve PNALD outcome. 
The ASPEN 2014 guidelines on PNALD failed to 
recommend ethanol locks of central PN catheters 
due to unresolved concerns regarding risks of 
thrombosis and disrupted catheter integrity.22  
UDCA: A retrospective cohort study23 
reported that cholestasis took longer to resolve in 64 
neonates treated with UDCA than in controls. This 
is not surprising since UDCA has minimum affinity 
to FXR as compared with the natural bile acid 
CDCA.   The ASPEN 2014 guidelines were unable 
to recommend UDCA treatment due to insufficient 
evidence in four analysed reports.  
Table 1: Strategies that may limit liver failure in PNALD 
Strategy Comment 
Start minimal enteral feeding early Reverses gut atrophy, may be poorly tolerated 
Advance enteral feeding Restores bile acid homeostasis 
Restrict calories administered as IVFE Other calorie sources need high infusion 
volumes 
Administer cyclic TPN Faster volume infusion  may be poorly 
tolerated  
Use fish based IVFE Theoretical risk of essential fatty acid 
deficiency 
Use mixed IVFEs Not adequately compared to fish-IVFEs 
Treat with ursodeoxycholic acid Poor efficacy as only weak FXR agonist 
Treat with potent FXR agonist ( Obeticholic 
acid) 
Favourable reports from phase 2 clinical trial 









                                                                                                                       
 
 
FXR agonists:  The above-mentioned ability 
of CDCA, a natural human BA to bind to the 
farnesoid X receptor (FXR) has prompted the 
synthesis of a 6α-ethyl derivative of CDCA called 
Obeticholic acid (OCA), a first-in-class drug that 
binds to FXR with 100 times more potency than 
CDCA.24 Phase II human clinical trials have shown 
that OCA is safe, and effective in reducing liver 
inflammation and fibrosis in type 2diabetes and 
non-alcoholic fatty liver (NAFLD), and in reducing 
serum alkaline phosphatase, a surrogate marker of 
risk of fibrotic progression in primary biliary 
cirrhosis. In addition to its ability to modulate liver 
regeneration after liver injury, FRX is expressed in 
human stellate cells in which it reduces expression 
of extracellular matrix proteins with a potential to 
reverse hepatic fibrosis which has already been 
demonstrated in rats.25 FRX agonist was more 




Available management strategies improve 
cholangitis in some PNALD scenarios but do not 
prevent fibrosis which appears to start very early in 
the course of the condition and which is often self-
perpetuating through stellate cell activation.  Of the 
two outcomes, prevention of fibrosis is likely to be 
more challenging than reversal of cholangitis. 
Perhaps the most effective strategy is to start enteral 
feeding early and to advance feeds while tapering 
PN. However, the patients with the highest 
mortality (typically premature / low birthweight, 
septic, and with acute enteric pathology such as 
necrotizing enterocolitis) will not tolerate this 
approach. The emerging challenge is to discover 
agents which will restore enteric hormonal, 
cytokine, and metabolic homeostatic responses 
during the early phase of intestinal failure. These 
could be bile acids,27 gut hormones or agonists to 
the various gut receptors such as FRX. Intense 
research in the field of NAFLD- cirrhosis is likely 
to discover new FRX agonist in other drug classes 
e.g. the nonsteroidal FXR agonist GW4064.28   
Comprehensive guidelines to manage and prevent 
PNALD should be based on RCTs that control for 
gestational age, birthweight, type and dose of IVFE, 
and length of residual functional small intestine 
with clearly defined endpoints,  such as the 
prevention or reversal of liver fibrosis and  the 
reversal of cholangitis. 
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